Prescribe by brand name

• 5mg & 10mg tablets
• 5mg, 10mg, 20mg, 30mg and 40mg m/r capsules (Medikinet® XL)
• 10mg, 20mg & 30mg m/r capsules (Equasym® XL)
• 18mg, 27mg, 36mg & 54mg m/r tablets (first choice: Atenza® XL; second choice: Xaggitin® XL)
  
  • Existing patients who are prescribed Concerta® XL should be reviewed and switched to an appropriate bioequivalent option
  • Atenza XL and Xaggitin XL are bioequivalent to Concerta XL
• 2mg/ml oral solution sugar free (Consilient Health Ltd). Only for those patients unable to take solid dosage forms across the whole dosage range. This preparation contains the following excipients with known effect: Propylene glycol 90mg/ml, Sorbitol 175mg/ml, Sodium benzoate 1mg/ml NPPG Position statement ‘Choosing an Oral Liquid Medicine for Children’ advises on maximum content of propylene glycol and benzoates dependent on age.

Approved for use: 

• in line with NENC shared care protocols in adults and children aged 6-17 years for treatment of:

  • ADHD
  •  Narcolepsy
• improving working memory and processing speed following neurocognitive damage secondary to brain injury from; a brain tumour and its associated treatment (e.g. hydrocephalus and radiotherapy) or neurotoxic chemotherapy.

See also: formulary entry in chapter 7 for management of giggle incontinence.

• 10mg, 18mg, 25mg, 40mg, 60mg, 80mg & 100mg capsules
• 4mg/1ml oral solution - approved for patients with more complex needs e.g. younger patients and those with swallowing difficulties.

Approved for use in line with NENC shared care protocols for treatment of ADHD in adults and children aged 6-17 years

• 5mg, 10mg and 20mg tablets

Approved for use in line with NENC shared care protocols in adults and children aged 6-17 years for treatment of:

• ADHD
•  Narcolepsy

• 20mg, 30mg, 40mg, 50mg, 60mg & 70mg capsules

Approved for use in line with NENC shared care protocols as a first line pharmacological treatment option for children aged 6-17 years and adults with ADHD who have been appropriately diagnosed, or as an alternative treatment when the response to a 6-week trial of methylphenidate is considered clinically inadequate.

• Approved for:
  
  • treatment of patients with narcolepsy
  • treatment of idiopathic hypersomnia
  
  
  

• 75mg and 150mg tablet
  • Approved for treating excesive daytime sleepiness caused by narcolepsy in line with NICE

• Approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
• To be used in line with NTAG

• 1mg, 2mg, 3mg & 4mg prolonged release tablets

Approved for use in line with NENC shared care protocols for treatment of ADHD in

• adults (off-label) - should only be considered on the advice of a tertiary ADHD service, for people who have not responded to one or more stimulants, and one non-stimulant
• children aged 6-17 years - for people who have not responded to one or more stimulants, and one non-stimulant